ARAY - Accuray Inc
(NaN%)
Sell
Weak Growth●Stock Price Very High
18%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -38.66%
Operating Income turning Positive
Net Income turning Positive
Earnings Per Share (EPS) is Zero
Net Margin is 0.14%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.64
Debt Ratio is 0.9
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.36
Cash Flow is WEAK
Cash from Operations turning Positive
Capital Expenditure is High
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Accuray Inc (ARAY) - http://www.accuray.com/
accuray incorporated (nasdaq: aray) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. the company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. for more information, please visit www.accuray.com. for career opportunities, please visit http://www.accuray.com/careers.Exchange - NASDAQ
Industry - Surgical and Medical Instrument Manufacturing
Sector - Manufacturing
CEO - Joshua Levine
Employees - 1,122
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.